Navigation Links
Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting

- Presentation to highlight milestones including phase III development of

'GI-friendly' NSAIDs for mild to moderate pain -

PALO ALTO, Calif., Oct. 5 /PRNewswire/ --

What: Horizon Therapeutics, Inc. is pleased to announce that

George Tidmarsh, M.D., Ph.D., chief executive officer, will

showcase Horizon's corporate and clinical milestones,

including its recent completion of Series C financing, and

provide an update on the development of the Company's

product pipeline during an Open House Podium Presentation

at BioPartnering Europe (BPE). Immediately following the

presentation Dr. Tidmarsh will be available to field

questions and provide more detailed information on Horizon


BPE was first held in London in 1993 as a partnership

between the U.S. Commercial Service and Technology Vision

Group LLC to bring about closer ties between American and

European biotechnology companies. From the beginning, BPE

has attracted the support of leading pharmaceutical,

biotechnology, financial and service companies that have

all contributed to making BPE one of the leading

independent partnering events in the world. BPE has a high

rate of sponsor retention, which indicates its prominent

position on the annual conference calendar for many

industry leaders.

When: Monday, October 8, 2007

9:30 a.m. - 12:45 p.m. Open House Podium Presentation

(10:45-10:55 a.m. Horizon presentation)

Where: London, England

QEII Conference Centre

Abbey Room West - Stream 1

Spokespeople: George Tidmarsh, M.D., Ph.D., co-founder and CEO of Horizon


Barry Golombik, co-founder of Horizon Therapeutics

Contact: Julie Normart

WeissComm Partners


About Horizon Therapeutics:

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit

SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. A new horizon
3. Conjoined Indian Twins See Hope On The Horizon
4. Stem cell cure for peripheral vascular disease: New hope on the horizon
5. Oral Flu Vaccine On The Horizon In Russia
6. Rescheduled: Aerial Mosquito Treatment for Philadelphia
7. First Keyhole Heart Valve Surgery Scheduled in Britain
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Researchers Present Ways To Reduce The Risk Of Dementia
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: